Lipid 03-135Featured
Price on request03-135 LNPs delivered mRNA encoding a CD19/CD3 T-cell engager and supported circulating antibody expression in mice.
CD19 × CD3 · mRNA · Intravenous
Study reference ↓
← All classifications
Applications & RNA cargo
Ionizable lipids for in vivo T-cell engager
Ionizable lipids with product-specific evidence for in vivo delivery of RNA encoding T-cell engagers (TCEs / BiTEs). Compare the antibody target, RNA format, model and administration route for each lipid.
5 products currently listedResearch-use products only
Evidence noteTCEs redirect T cells by binding a target-cell antigen and CD3. Inclusion reflects the cited formulation and experiment; it does not establish direct T-cell delivery, clinical equivalence or product performance.
RNA-encoded T-cell engagers
CD19 · CLDN6 · B7H3
mRNA and self-amplifying RNA delivery
5 lipids · Intravenous evidence
View study references ↓Cat. No.Product NameField of ApplicationChemical Structure
Lipid 01-1Featured
Price on request01-1 LNPs were used for CD19/CD3 T-cell engager expression and antitumor experiments in a human PBMC-engrafted Nalm6 leukemia model.
CD19 × CD3 · mRNA · Intravenous
Study reference ↓
ALC-0366Featured
ALC-0366 is explicitly listed in the BNT142 formulation encoding the CLDN6/CD3 engager RiboMab02.1; the patent reports in vivo expression and pharmacokinetic studies.
CLDN6 × CD3 · mRNA (BNT142) · Intravenous
Study reference ↓
IC-8(lipid MIC5)Featured
IC8 LNPs delivered B7H3/CD3 BiTE-encoding mRNA, with in vivo antibody expression and antitumor experiments in mouse xenograft models.
B7H3 × CD3 · mRNA · Intravenous
Study reference ↓
SM-102Featured
SM-102 LNPs delivered self-amplifying RNA encoding a CLDN6 nanobody-based T-cell engager, with circulating expression and antitumor studies in mice.
CLDN6 × CD3 · Self-amplifying RNA · Intravenous
Study reference ↓
No products match this search.
Evidence for category inclusion
Study-specific findings for research-use lipid selection.
DCL0008 · Lipid 03-135 — Patent evidence
03-135 LNPs delivered mRNA encoding a CD19/CD3 T-cell engager and supported circulating antibody expression in mice. Route: Intravenous.
DCL0009 · Lipid 01-1 — Patent evidence
01-1 LNPs were used for CD19/CD3 T-cell engager expression and antitumor experiments in a human PBMC-engrafted Nalm6 leukemia model. Route: Intravenous.
WO2024131874A1, Example 7, paragraphs [0362–0363], Figures 3B and 4A–4B.
DC60478 · ALC-0366 — Patent evidence
ALC-0366 is explicitly listed in the BNT142 formulation encoding the CLDN6/CD3 engager RiboMab02.1; the patent reports in vivo expression and pharmacokinetic studies. Route: Intravenous.
DC82301 · IC-8 (IC8; lipid MIC5) — Peer-reviewed study
IC8 LNPs delivered B7H3/CD3 BiTE-encoding mRNA, with in vivo antibody expression and antitumor experiments in mouse xenograft models. Route: Intravenous.
DC52025 · SM-102 — Peer-reviewed study
SM-102 LNPs delivered self-amplifying RNA encoding a CLDN6 nanobody-based T-cell engager, with circulating expression and antitumor studies in mice. Route: Intravenous.
Each entry refers to the full RNA-LNP formulation in the cited study. These studies do not establish subcutaneous performance or guaranteed efficacy of the supplied lipid.